Stevanato Group S.p.A. (STVN)

NYSE: STVN · Real-Time Price · USD

22.92

-0.44 (-1.88%)

At close: Dec 4, 2025, 4:00 PM EST

22.50

-0.42 (-1.83%)

Pre-market: Dec 5, 2025, 7:01 AM EST

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2018 - 2020
EMEA Revenue	692.77M	667.83M	Log In	Log In	Log In	Upgrade
APAC Revenue	101.03M	96.24M	Log In	Log In	Log In	Upgrade
North America Revenue	321.83M	308.95M	Log In	Log In	Log In	Upgrade
South America Revenue	29.47M	31.02M	Log In	Log In	Log In	Upgrade
Revenue (Other)	1,000.00	1,000.00	Log In	Log In	Log In	Upgrade
Revenue (Total)	1.15B	1.10B	Log In	Log In	Log In	Upgrade

Revenue

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2018 - 2020
Biopharmaceutical and Diagnostic Solutions Revenue	976.82M	933.74M	Log In	Log In	Log In	Upgrade
Engineering Revenue	168.28M	170.29M	Log In	Log In	Log In	Upgrade
Revenue (Total)	1.15B	1.10B	Log In	Log In	Log In	Upgrade

Gross Profit

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2018 - 2020
Biopharmaceutical and Diagnostic Solutions Gross Profit	298.47M	268.78M	Log In	Log In	Log In	Upgrade
Engineering Gross Profit	47.14M	56.17M	Log In	Log In	Log In	Upgrade
Eliminations from Gross Profit	-24.54M	-22.63M	Log In	Log In	Log In	Upgrade
Gross Profit (Other)	1,000.00	-	Log In	Log In	Log In	Upgrade
Gross Profit (Total)	321.08M	302.32M	Log In	Log In	Log In	Upgrade

EBIT

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2018 - 2020
Biopharmaceutical and Diagnostic Solutions Operating Profit	193.51M	165.64M	Log In	Log In	Log In	Upgrade
Engineering Operating Profit	28.95M	33.10M	Log In	Log In	Log In	Upgrade
Eliminations from Operating Profit	-38.58M	-37.59M	Log In	Log In	Log In	Upgrade
Operating Income (Total)	183.88M	161.14M	Log In	Log In	Log In	Upgrade

Key Performance Indicators

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2018 - 2020
Backlog	853.00M	Log In	Log In	Log In	Upgrade

Updated Nov 6, 2025. Data Source: Fiscal.ai.